Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: From patients enrolled in clinical trials to those in the 'real world'

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2014, Pages 20-28

  Fujita, Ken Ichi ^a   Sasaki, Yasutsuna ^a,b  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Advanced age; Cancer chemotherapy; Irinotecan; OATP1B1; Obesity; Organ dysfunction; Renal failure; S 1; SN 38

Indexed keywords

CYTOCHROME P450 2A6; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

AREA UNDER THE CURVE; BLOOD TOXICITY; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NEUTROPHIL COUNT; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS; POLYPHARMACY; RECOMMENDED DRUG DOSE; REVIEW; STOMACH CANCER;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG MONITORING; HUMANS; NEOPLASMS; OBESITY; OXONIC ACID; PATIENT SELECTION; POLYPHARMACY; RENAL INSUFFICIENCY; TEGAFUR;

EID: 84898411176     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RV-103     Document Type: Review

References (109)

1. Hall, B. E., Willett, F. M., Feichtmeir, T. V., Reed, E. B. and Dowling, W. F.: Current trends in cancer chemotherapy. Calif. Med., 84: 1-9 (1956).
2. Lyman, G. H.: Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl. Compr. Canc. Netw., 7: 99-108 (2009).
3. Launay-Vacher, V., Chatelut, E., Lichtman, S. M., Wildiers, H., Steer, C. and Aapro, M.: International Society of Geriatric, O.: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann. Oncol., 18: 1314-1321 (2007).
4. Janus, N., Thariat, J., Boulanger, H., Deray, G. and Launay-Vacher, V.: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann. Oncol., 21: 1395-1403 (2010).
5. Lyman, G. H. and Sparreboom, A.: Chemotherapy dosing in overweight and obese patients with cancer. Nat. Rev. Clin. Oncol., 10: 451-459 (2013).
6. Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., et al.: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol., 30: 1553-1561 (2012).
7. Lichtman, S. M., Wildiers, H., Chatelut, E., Steer, C., Budman, D., Morrison, V. A., Tranchand, B., Shapira, I., Aapro, M., et al.: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J. Clin. Oncol., 25: 1832-1843 (2007).
8. Hurria, A. and Lichtman, S. M.: Pharmacokinetics of chemotherapy in the older patient. Cancer Control, 14: 32-43 (2007).
9. Lichtman, S. M., Wildiers, H., Launay-Vacher, V., Steer, C., Chatelut, E. and Aapro, M.: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur. J. Cancer, 43: 14-34 (2007).
10. Simon, R.: Design and analysis of clinical trials. In Devita, V. T., Lawrence, T. S. and Rosenberg, S. A. (eds.): Cancer Principles & Practice of Oncology, Philadelphia, Lippincott Wiliams & Wilkins, 2011, pp. 704-722.
11. Roberts, T. G., Jr., Goulart, B. H., Squitieri, L., Stallings, S. C., Halpern, E. F., Chabner, B. A., Gazelle, G. S., Finkelstein, S. N. and Clark, J. W.: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA, 292: 2130-2140 (2004).
12. Simon, R.: Randomized clinical trials in oncology. Principles and obstacles. Cancer, 74: 2614-2619 (1994).
13. Roberts, T. G., Jr., Lynch, T. J., Jr. and Chabner, B. A.: The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J. Clin. Oncol., 21: 3683-3695 (2003).
14. Gilman, A.: The initial clinical trial of nitrogen mustard. Am. J. Surg., 105: 574-578 (1963).
15. Minami, H., Ando, Y., Sakai, S. and Shimokata, K.: Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J. Clin. Oncol., 13: 191-199 (1995).
16. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E. and Ratain, M. J.: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol., 15: 1502-1510 (1997).
17. Yamamoto, N., Tamura, T., Murakami, H., Shimoyama, T., Nokihara, H., Ueda, Y., Sekine, I., Kunitoh, H., Ohe, Y., et al.: Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J. Clin. Oncol., 23: 1061-1069 (2005).
18. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G. and Egorin, M. J.: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190 (1995).
19. Latz, J. E., Schneck, K. L., Nakagawa, K., Miller, M. A. and Takimoto, C. H.: Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients. Clin. Cancer Res., 15: 346-354 (2009).
20. Minami, H., Ohe, Y., Niho, S., Goto, K., Ohmatsu, H., Kubota, K., Kakinuma, R., Nishiwaki, Y., Nokihara, H., et al.: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J. Clin. Oncol., 22: 2901-2908 (2004).
21. Gamelin, E. C., Danquechin-Dorval, E. M., Dumesnil, Y. F., Maillart, P. J., Goudier, M. J., Burtin, P. C., Delva, R. G., Lortholary, A. H., Gesta, P. H., et al.: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer, 77: 441-451 (1996).
22. Milano, G., Etienne, M. C., Renee, N., Thyss, A., Schneider, M., Ramaioli, A. and Demard, F.: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol., 12: 1291-1295 (1994).
23. Powis, G.: Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat. Rev., 9: 85-124 (1982).
24. Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N. and Roth, D.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med., 130: 461-470 (1999).
25. Cockcroft, D. W. and Gault, M. H.: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41 (1976).
26. Ciarimboli, G., Lancaster, C. S., Schlatter, E., Franke, R. M., Sprowl, J. A., Pavenstadt, H., Massmann, V., Guckel, D., Mathijssen, R. H., et al.: Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin. Cancer Res., 18: 1101-1108 (2012).
27. Stevens, L. A., Coresh, J., Greene, T. and Levey, A. S.: Assessing kidney function-measured and estimated glomerular filtration rate. N. Engl. J. Med., 354: 2473-2483 (2006).
28. Kusuhara, H. and Sugiyama, Y.: In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet., 24: 37-52 (2009).
29. Raymond, E., Boige, V., Faivre, S., Sanderink, G. J., Rixe, O., Vernillet, L., Jacques, C., Gatineau, M., Ducreux, M., et al.: Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol., 20: 4303-4312 (2002).
30. Hammerlein, A., Derendorf, H. and Lowenthal, D. T.: Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin. Pharmacokinet., 35: 49-64 (1998).
31. Bach, B., Hansen, J. M., Kampmann, J. P., Rasmussen, S. N. and Skovsted, L.: Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin. Pharmacokinet., 6: 389-396 (1981).
32. Durnas, C., Loi, C. M. and Cusack, B. J.: Hepatic drug metabolism and aging. Clin. Pharmacokinet., 19: 359-389 (1990).
33. Sotaniemi, E. A., Arranto, A. J., Pelkonen, O. and Pasanen, M.: Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin. Pharmacol. Ther., 61: 331-339 (1997).
34. Lichtman, S. M. and Skirvin, J. A.: Pharmacology of antineoplastic agents in older cancer patients. Oncology (Williston Park), 14: 1743-1755; discussion 1755, passim (2000).
35. Lichtman, S. M., Skirvin, J. A. and Vemulapalli, S.: Pharmacology of antineoplastic agents in older cancer patients. Crit. Rev. Oncol. Hematol., 46: 101-114 (2003).
36. Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L. and Brown, M.: Health and economic burden of the projected obesity trends in the USA and the UK. Lancet, 378: 815-825 (2011).
37. Meyerhardt, J. A. and Mayer, R. J.: Systemic therapy for colorectal cancer. N. Engl. J. Med., 352: 476-487 (2005).
38. Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med., 346: 85-91 (2002).
39. Kubota, K., Watanabe, K., Kunitoh, H., Noda, K., Ichinose, Y., Katakami, N., Sugiura, T., Kawahara, M., Yokoyama, A., et al.: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol., 22: 254-261 (2004).
40. Mathijssen, R. H., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G. and Sparreboom, A.: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 7: 2182-2194 (2001).
41. Sparreboom, A., Fujita, K. and Zamboni, W. C.: Topoisomerase I-Targeting Drugs. In Chabner, B. A. and Longo, D. L. (eds.): Cancer Chemotherapy and Biotherapy Principles and Practice, Philadelphia, Lippincott Williams & Wilkins, 2010, pp. 342-355.
42. Chu, X. Y., Kato, Y. and Sugiyama, Y.: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938 (1997).
43. Chu, X. Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., et al.: Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res., 58: 5137-5143 (1998).
44. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., et al.: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832 (2001).
45. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A. and Tamai, I.: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos., 33: 434-439 (2005).
46. Yamaguchi, H., Kobayashi, M., Okada, M., Takeuchi, T., Unno, M., Abe, T., Goto, J., Hishinuma, T. and Mano, N.: Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett., 260: 163-169 (2008).
47. Fujita, K. I., Sugiura, T., Okumura, H., Umeda, S., Nakamichi, N., Watanabe, Y., Suzuki, H., Sunakawa, Y., Shimada, K., et al.: Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans. Pharm. Res. (2013). [Epub ahead of print]
48. Mathijssen, R. H., de Jong, F. A., Loos, W. J., van der Bol, J. M., Verweij, J. and Sparreboom, A.: Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist, 12: 913-923 (2007).
49. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E. and Ratain, M. J.: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725 (1994).
50. Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N., Jansen, P. L., et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med., 333: 1171-1175 (1995).
51. Beutler, E., Gelbart, T. and Demina, A.: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA, 95: 8170-8174 (1998).
52. Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Wakabayashi, T., Hiroi, M., Yasumura, S., Maki, K., Aikawa, S., et al.: Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J. Hum. Genet., 44: 22-25 (1999).
53. Gagne, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G. and Guillemette, C.: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol., 62: 608-617 (2002).
54. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 60: 6921-6926 (2000).
55. Han, J. Y., Lim, H. S., Shin, E. S., Yoo, Y. K., Park, Y. H., Lee, J. E., Jang, I. J., Lee, D. H. and Lee, J. S.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol., 24: 2237-2244 (2006).
56. Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramirez, J., et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol., 22: 1382-1388 (2004).
57. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J., Hamaguchi, T., et al. : Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and * 28. Pharmacogenet. Genomics, 17: 497-504 (2007).
58. de Jong, F. A., Kitzen, J. J., de Bruijn, P., Verweij, J. and Loos, W. J.: Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol. Ther., 5: 1105-1110 (2006).
59. Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., et al.: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos., 28: 423-433 (2000).
60. Sparreboom, A., de Jonge, M. J., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H., Stoter, G., et al.: Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res., 4: 2747-2754 (1998).
61. Fujita, K., Sunakawa, Y., Miwa, K., Akiyama, Y., Sugiyama, M., Kawara, K., Ishida, H., Yamashita, K., Mizuno, K., et al.: Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab. Dispos., 39: 161-164 (2011).
62. Kehrer, D. F., Yamamoto, W., Verweij, J., de Jonge, M. J., de Bruijn, P. and Sparreboom, A.: Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin. Cancer Res., 6: 3451-3458 (2000).
63. de Jong, F. A., van der Bol, J. M., Mathijssen, R. H., van Gelder, T., Wiemer, E. A., Sparreboom, A. and Verweij, J.: Renal function as a predictor of irinotecan-induced neutropenia. Clin. Pharmacol. Ther., 84: 254-262 (2008).
64. de Jong, F. A., van der Bol, J. M., Mathijssen, R. H., van Gelder, T., Wiemer, E. A., Sparreboom, A. and Verweij, J.: Renal function as a predictor of irinotecan-induced neutropenia. Clin. Pharmacol. Ther., 84: 254-262 (2008).
65. Kajosaari, L. I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P. J. and Backman, J. T.: Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther., 78: 388-399 (2005).
66. Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J. and Niemi, M.: Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin. Pharmacol. Ther., 84: 488-496 (2008).
67. Marbury, T. C., Ruckle, J. L., Hatorp, V., Andersen, M. P., Nielsen, K. K., Huang, W. C. and Strange, P.: Pharmacokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther., 67: 7-15 (2000).
68. Zhao, P., Vieira Mde, L., Grillo, J. A., Song, P., Wu, T. C., Zheng, J. H., Arya, V., Berglund, E. G., Atkinson, A. J., Jr., et al.: Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol., 52: 91S-108S (2012).
69. Kitamura, S., Maeda, K., Wang, Y. and Sugiyama, Y.: Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos., 36: 2014-2023 (2008).
70. Huang, S. M., Temple, R., Xiao, S., Zhang, L. and Lesko, L. J.: When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin. Pharmacol. Ther., 86: 475-479 (2009).
71. Sparreboom, A., Wolff, A. C., Mathijssen, R. H., Chatelut, E., Rowinsky, E. K., Verweij, J. and Baker, S. D.: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J. Clin. Oncol., 25: 4707-4713 (2007).
72. Sasaki, T., Fujita, K., Sunakawa, Y., Ishida, H., Yamashita, K., Miwa, K., Saji, S., Kato, Y. and Sasaki, Y.: Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. Int. J. Clin. Oncol., 18: 735-742 (2013).
73. Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol., 10: 1063-1069 (2009).
74. Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol., 9: 215-221 (2008).
75. Ohtsu, A., Yoshida, S. and Saijo, N.: Disparities in gastric cancer chemotherapy between the East and West. J. Clin. Oncol., 24: 2188-2196 (2006).
76. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., et al.: Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606 (1996).
77. Ikeda, K., Yoshisue, K., Matsushima, E., Nagayama, S., Kobayashi, K., Tyson, C. A., Chiba, K. and Kawaguchi, Y.: Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin. Cancer Res., 6: 4409-4415 (2000).
78. Tatsumi, K., Fukushima, M., Shirasaka, T. and Fujii, S.: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res., 78: 748-755 (1987).
79. Shiotani, T. and Weber, G.: Purification and properties of dihydrothymine dehydrogenase from rat liver. J. Biol. Chem., 256: 219-224 (1981).
80. Shirasaka, T., Shimamoto, Y. and Fukushima, M.: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res., 53: 4004-4009 (1993).
81. Takechi, T., Nakano, K., Uchida, J., Mita, A., Toko, K., Takeda, S., Unemi, N. and Shirasaka, T.: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol., 39: 205-211 (1997).
82. Fujita, K., Yamamoto, W., Endo, S., Endo, H., Nagashima, F., Ichikawa, W., Tanaka, R., Miya, T., Araki, K., et al.: CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci., 99: 1049-1054 (2008).
83. Nakajima, M., Fukami, T., Yamanaka, H., Higashi, E., Sakai, H., Yoshida, R., Kwon, J. T., McLeod, H. L. and Yokoi, T.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther., 80: 282-297 (2006).
84. Nakajima, M., Yoshida, R., Fukami, T., McLeod, H. L. and Yokoi, T.: Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett., 569: 75-81 (2004).
85. Nunoya, K., Yokoi, T., Kimura, K., Inoue, K., Kodama, T., Funayama, M., Nagashima, K., Funae, Y., Green, C., et al.: A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 8: 239-249 (1998).
86. Ariyoshi, N., Sawamura, Y. and Kamataki, T.: A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem. Biophys. Res. Commun., 281: 810-814 (2001).
87. Kiyotani, K., Yamazaki, H., Fujieda, M., Iwano, S., Matsumura, K., Satarug, S., Ujjin, P., Shimada, T., Guengerich, F. P., et al.: Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics, 13: 689-695 (2003).
88. Yoshida, R., Nakajima, M., Nishimura, K., Tokudome, S., Kwon, J. T. and Yokoi, T.: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther., 74: 69-76 (2003).
89. Hirata, K., Horikoshi, N., Aiba, K., Okazaki, M., Denno, R., Sasaki, K., Nakano, Y., Ishizuka, H., Yamada, Y., et al.: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin. Cancer Res., 5: 2000-2005 (1999).
90. Kim, K. P., Jang, G., Hong, Y. S., Lim, H. S., Bae, K. S., Kim, H. S., Lee, S. S., Shin, J. G., Lee, J. L., et al.: Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br. J. Cancer, 104: 605-612 (2011).
91. Niwa, T., Shiraga, T., Ohno, Y. and Kagayama, A.: Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol. Pharm. Bull., 28: 1071-1074 (2005).
92. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
93. Fujita, K., Ichikawa, W., Yamamoto, W., Endo, H., Nagashima, F., Tanaka, R., Miya, T., Araki, K., Kodama, K., et al.: Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. Ann. Oncol., 20: 946-949 (2009).
94. Gurney, H.: Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol., 14: 2590-2611 (1996).
95. Moller, E., McIntosh, J. F. and Van Slyke, D. D.: STUDIES OF UREA EXCRETION. II: Relationship Between Urine Volume and the Rate of Urea Excretion by Normal Adults. J. Clin. Invest., 6: 427-465 (1928).
96. Lee, J. L., Kang, Y. K., Kang, H. J., Lee, K. H., Zang, D. Y., Ryoo, B. Y., Kim, J. G., Park, S. R., Kang, W. K., et al.: A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer, 99: 584-590 (2008).
97. Yamada, Y., Hamaguchi, T., Goto, M., Muro, K., Matsumura, Y., Shimada, Y., Shirao, K. and Nagayama, S.: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br. J. Cancer, 89: 816-820 (2003).
98. Fujita, K., Nakayama, H., Ichikawa, W., Yamamoto, W., Endo, H., Nagashima, F., Tanaka, R., Miya, T., Sunakawa, Y., et al.: Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine). Drug Metab. Dispos., 37: 1375-1377 (2009).
99. Brenner, B. M., Meyer, T. W. and Hostetter, T. H.: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med., 307: 652-659 (1982).
100. Dupuis, C., Mercier, C., Yang, C., Monjanel-Mouterde, S., Ciccolini, J., Fanciullino, R., Pourroy, B., Deville, J. L., Duffaud, F., et al.: High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs, 19: 267-273 (2008).
101. Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M. and Gurney, H.: Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol., 30: 4017-4025 (2012).
102. Gamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J. L., Pezet, D., Dorval, E., Piot, G., Morel, A., et al.: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol., 26: 2099-2105 (2008).
103. Taguchi, T., Inuyama, Y., Kanamaru, R., Hasegawa, K., Akazawa, S., Niitani, H., Furue, H., Kurihara, M., Ota, K., et al.: [Phase I study of S-1. S-1 Study Group]. Gan To Kagaku Ryoho, 24: 2253-2264 (1997).
104. van Groeningen, C. J., Peters, G. J., Schornagel, J. H., Gall, H., Noordhuis, P., de Vries, M. J., Turner, S. L., Swart, M. S., Pinedo, H. M., et al.: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J. Clin. Oncol., 18: 2772-2779 (2000).
105. Ajani, J. A., Faust, J., Ikeda, K., Yao, J. C., Anbe, H., Carr, K. L., Houghton, M. and Urrea, P.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol., 23: 6957-6965 (2005).
106. Cohen, S. J., Leichman, C. G., Yeslow, G., Beard, M., Proefrock, A., Roedig, B., Damle, B., Letrent, S. P., DeCillis, A. P., et al. : Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin. Cancer Res., 8: 2116-2122 (2002).
107. Cengiz, K.: Increased incidence of neoplasia in chronic renal failure (20-year experience). Int. Urol. Nephrol., 33: 121-126 (2002).
108. Matas, A. J., Simmons, R. L., Kjellstrand, C. M., Buselmeier, T. J. and Najarian, J. S.: Increased incidence of malignancy during chronic renal failure. Lancet, 1: 883-886 (1975).
109. Sutherland, G. A., Glass, J. and Gabriel, R.: Increased incidence of malignancy in chronic renal failure. Nephron, 18: 182-184 (1977).